Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-04-05
2011-04-05
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S121000
Reexamination Certificate
active
07919492
ABSTRACT:
Compounds of formula (I)wherein R1is 2-indanyl, R2is 1-methylpropyl, R3is a group selected from 2,6-dimethyl-3-pyridyl or 4,6-dimethyl-3-pyridyl, R4represents methyl and R5represents hydrogen or methyl or, R4and R5together with the nitrogen atom to which they are attached represent morpholino and pharmaceutically acceptable derivatives thereof are described, as are processes for their preparation, pharmaceutical compositions containing them and their use in medicine, particularly their use as oxytocin antagonists.
REFERENCES:
patent: 4596819 (1986-06-01), Nicolaides et al.
patent: 5464788 (1995-11-01), Bock et al.
patent: 5817751 (1998-10-01), Szardenings et al.
patent: 7550462 (2009-06-01), Borthwick et al.
patent: 2005/0148572 (2005-07-01), Borthwick et al.
patent: 2007/0149524 (2007-06-01), Liddle
patent: 2007/0185162 (2007-08-01), Borthwick et al.
patent: 2007/0208031 (2007-09-01), Borthwick et al.
patent: 3830096 (2004-01-01), None
patent: 2326639 (1998-12-01), None
patent: 9937304 (1999-07-01), None
patent: 9938844 (1999-08-01), None
patent: 9947549 (1999-09-01), None
patent: 03053443 (2003-07-01), None
patent: 2005000311 (2005-01-01), None
patent: 2005000840 (2005-01-01), None
patent: 2006000400 (2006-01-01), None
patent: 2006000759 (2006-06-01), None
patent: 2006067462 (2006-06-01), None
Waldinger, Drugs,vol. 67, No. 4, pp. 547-568 (2007).
Clement et al. British Journal of Pharmacology, vol. 154, pp. 1150-1159 (2008).
Vippagunta et al.; Advanced Drug Delivery Reviews; 2001; vol. 48; pp. 3-26.
Akerlund; Prog. Brain. Res.; 2002; vol. 139; pp. 359-365.
Tsatsaris et al.; Drugs; 2004; vol. 64(4) Abstract; pp. 375-382.
Wolff; Burger's Medicinal Chemistry, 5th Ed., Part 1; 1995; pp. 975-977.
Testa et al.; Pure Appl. Chem.; 2004; vol. 76; pp. 907-914.
Banker et al.; Modern Pharmaceutics, 3rd Ed.; 1996; p. 596.
Grigorash et al.; Chem. Heterocycl. Compound; 1977; vol. 13, No. 12; pp. 1280-1281.
Kolasa et al.; J. Org. Chem.; 1990; vol. 55, No. 6; pp. 1711-1721.
Pettibone et al.; Drug Development Research; 1993; vol. 30, No. 3; pp. 129-142.
Wyatt et al.; Bioorganic & Med. Chem. Letters; 2001; vol. 11, No. 10; pp. 1301-1305.
Stella; “Pro Drugs: An Overview and Definition”; Pro Drugs as Novel Drug Delivery Systems; 1975; Chapter 1; pp. 1-115.
Borthwick Alan David
Hickey Deirdre Mary Bernadette
Liddle John
Mason Andrew McMurtrie
Bernhardt Emily
Coulter Kathryn L.
Glaxo Group Limited
Peng Tony W.
LandOfFree
Compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2705142